Two Sigma Advisers
TAK icon

Two Sigma Advisers’s Takeda Pharmaceutical TAK Stock Holding History

Two Sigma Advisers’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-298,400
Closed -$4.65M – 1898
2025
Q4 		$4.65M Buy
298,400
+91,200
+44% +$1.3M 0.01% 845
2025
Q3 		$3.03M Buy
207,200
+54,700
+36% +$812K 0.01% 943
2025
Q2 		$2.36M Sell
152,500
-2,100
-1% -$31K ﹤0.01% 1037
2025
Q1 		$2.3M Hold
154,600
– – 0.01% 1103
2024
Q4 		$2.05M Buy
154,600
+121,500
+367% +$1.67M ﹤0.01% 1114
2024
Q3 		$471K Buy
+33,100
New +$469K ﹤0.01% 1736
2023
Q2 		– Sell
-87,900
Closed -$1.45M – 2653
2023
Q1 		$1.45M Buy
87,900
+56,991
+184% +$908K ﹤0.01% 1444
2022
Q4 		$482K Sell
30,909
-86,491
-74% -$1.21M ﹤0.01% 1891
2022
Q3 		$1.52M Sell
117,400
-62,057
-35% -$863K ﹤0.01% 1314
2022
Q2 		$2.52M Buy
179,457
+37,557
+26% +$536K 0.01% 1095
2022
Q1 		$2.03M Buy
+141,900
New +$2.08M 0.01% 1244
2021
Q2 		– Sell
-100,800
Closed -$1.84M – 2687
2021
Q1 		$1.84M Buy
+100,800
New +$1.81M 0.01% 1306

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Two Sigma Advisers's TAK Position: Q1 2026 in Review

Two Sigma Advisers sold out of Takeda Pharmaceutical (TAK) in Q1 2026, closing a stake of 298,400 shares — an estimated $4.65M sold.

Two Sigma Advisers first reported a position in TAK in Q1 2021 and held it in 12 quarters. The position peaked at $4.65M in Q4 2025. 361 funds tracked by Wall St. Rank hold TAK as of Q1 2026.

  • Two Sigma Advisers reported no remaining Takeda Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 298,400 Takeda Pharmaceutical shares in Q1 2026, an estimated $4.65M.
  • Two Sigma Advisers first reported a position in Takeda Pharmaceutical in Q1 2021 and held it in 12 quarters.
  • Two Sigma Advisers's Takeda Pharmaceutical position peaked at $4.65M in Q4 2025.
  • 361 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.